CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Crizotinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04283669
NCT04283669Phase 2Completed
CompareCT.gov

Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

University of Alabama at Birmingham·interventional·Posted Feb 25, 2020·Updated Mar 13, 2026

In Brief

A Phase 2 clinical trial evaluating Crizotinib for Neurofibromatosis 2 and Progressive Vestibular Schwannoma (VS). Completed, enrolled 12 participants across 15 sites.

Detailed Summary

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurofibromatosis 2, Progressive Vestibular Schwannoma (VS)
CountriesUnited States
CollaboratorsMemorial Sloan Kettering Cancer Center, Children's Hospital of Philadelphia

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 25, 2020
Enrollment StartFeb 18, 2020
Primary CompletionFeb 25, 2025
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 6.4 years ago

Interventions

Crizotinibdrug

Oral